A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

NCT02493738 | Completed Phase 1 DMC

• 1 other identifier: BR-ITR-CT-101
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Study Objectives:

• To evaluate the pharmacokinetics (PK) of orally administered Lozanoc under fasted and fed condition in healthy male subjects
• To compare the pharmacokinetics (PK) of orally administered Lozanoc and Sporanox under fed condition in healthy male subjects
• To evaluate the safety and tolerability of single oral dose of Lozanoc and Sporanox in Korean healthy male subjects

Conditions

Superficial Mycoses; Dermatomycoses; Candidiasis; Histoplasmosis

Outcome Measures

Primary Outcomes (1)

• Cmax

  0~120 hour after medication

Secondary Outcomes (2)

• tmax

  0~120 hour after medication

• AUCinf

  0~120 hour after medication

Study Arms (2)

Lozanoc 50mg

EXPERIMENTAL

Lozanoc 50mg, oral administration

Drug: Lozanoc 50mg

Sporanox 100mg

ACTIVE COMPARATOR

Sporanox 100mg, oral administration

Drug: Sporanox 100mg

Interventions

Lozanoc 50mg DRUG

Lozanoc 50mg single dose under fed and fasted condition

Lozanoc 50mg

Sporanox 100mg DRUG

Sporanox 100mg single dose under fed condition

Sporanox 100mg

Eligibility Criteria

• Age: 19 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Korean male volunteers in the age between 19 and 50 years old (inclusive)
• Subject who are able to give signed informed consent
• Body mass index (BMI) in the range of 19 to 28 kg/m2 and weighting at least 50kg
• Subject who are considered
• Pre-study physical examination with no clinically significant abnormalities
• No clinically significant medical history
• Vital signs were to be within reference ranges, or if outside of the range, not deemed clinically significant in the opinion of the Investigator
• mmHg ≤ systolic blood pressure (sitting position) ≤ 140mmHg
• mmHg ≤ diastolic blood pressure (sitting position) ≤ 90 mmHg
• Pre-study clinical laboratory findings were to be within reference range, or if outside of the range, not deemed clinically significant in the opinion of the Investigator
• No clinically significant abnormalities in 12-lead ECG results
• Agree to continue to use at least two accepted methods of birth control and not to donate sperm for at least 1 days before the first dosing, during the course of the study and for a period of 90days following the last dosing.
• Acceptable methods of birth control are: female (sexual partner) hormonal contraceptives; intrauterine device; surgical sterility at least 6 months prior to screening (Ex. hysterectomy, bilateral oophorectomy, and/or tubal ligation); use diaphragm; use condom; or spermicide

You may not qualify if:

• Subjects will be excluded if they meet any of the following criteria:
• History of allergy or sensitivity to any drug, including any prior serious adverse reaction to antifungal agent(s)
• History of congestive heart failure or Patients with ventricular dysfunction such as congestive heart failure
• Undergone surgery or who have a medical condition, that in the judgment of the Investigator, may affect absorption, distribution, metabolism or elimination of the drug product
• Participated in a previous clinical trial within 90 days prior to screening visit
• Donated blood or had a significant loss of blood within 60 days prior to screening visit
• Special diet or substantial changes in eating habits within 30 days prior to screening visit
• Use of any prescription medication within 14 days before screening visit
• Use of any other OTC medication within the 7 days before screening visit
• History of smoking within 3 months prior to screening visit
• Have a recent history (within 2 years prior to the screening visit) of alcohol or drug abuse or a positive screen for drugs of abuse at screening
• Positive blood screen for HIV or hepatitis B or C or syphilis
• Clinically important abnormal hepatic function test (AST, ALT greater than 2 fold of reference upper limit (ULN), or total bilirubin greater than 1.5 x ULN)
• Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol

Sponsors & Collaborators

• Boryung Pharmaceutical Co., Ltd: lead

Study Sites (1)

Asan Medical Center

Seoul, South Korea

Location

MeSH Terms

Conditions

Dermatomycoses; Candidiasis; Histoplasmosis

Interventions

Itraconazole

Condition Hierarchy (Ancestors)

Mycoses; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperazines

Study Officials

• Kyun-Seop Bae, M.D., Ph.D.

  Department of Clinical Pharmacology and Therapeutics, Asan Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2015
• First Posted: July 9, 2015
• Study Start: July 1, 2015
• Primary Completion: October 1, 2015
• Study Completion: October 1, 2015
• Last Updated: March 4, 2016

Record last verified: 2016-03

Locations

KR (1)